ASIA CEO Community

Dr. Cheng received medical degree in Shanghai Medical University, Ph.D. in New York University School of Medicine, and completed post-doctoral fellowship at Rockefeller University and MD Anderson Cancer. Dr. Cheng became a faculty at Penn State Cancer Institute and University of Maryland Cancer Center prior to funding Immucision Biotherapeutics. Dr. Cheng is an experienced scientist in medical virology, cancer biology and immunotherapy, and an inventor for more than 20 patents.
The company background
Immucision Biotherapeutics is at the forefront of next‑generation cancer immunotherapy, leveraging a proprietary dendritic cell engineering platform that redefines the potential of cell‑based vaccines. Our engineered dendritic cells (eDC) are not only exceptionally valuable as standalone cancer vaccines but also serve as a versatile foundation for generating a range of derivative cell therapy modules. Unlike conventional DC methods, our eDC technology enables the development of complementary immune effector cells—including natural killer (NK), natural killer T (NKT), Tγδ T cells, and tumor‑infiltrating lymphocytes (TILs)—as well as innovative DC exosome nanotechnology for targeted drug delivery.